Medicus Pharma Q2 net loss widens as operating expenses rise

Medicus Pharma

12/08/2026 23:09

Overview
US biotech firm's Q2 net loss widened and operating expenses increased yr/yr
Company raised ~$40 mln in equity and debt, boosting liquidity but faces going concern risk
Company achieved key FDA and international study authorizations for SkinJect and Teverelix programs

Outlook
Company expects multiple clinical and regulatory milestones in coming quarters across core programs
Medicus anticipates potential expansion of strategic collaborations and licensing discussions
Company says substantial doubt exists about ability to continue as a going concern without more financing

Result Drivers
R&D SPENDING - Research and development expenses rose to $4.9 mln from $1.4 mln in Q2 2025 as co advanced clinical programs
REGULATORY MILESTONES - Co cited FDA and international study authorizations for SkinJect and Teverelix as key achievements supporting pipeline progress
HIGHER OPERATING COSTS - Operating expenses increased to $11.5 mln from $6.0 mln in Q2 2025, reflecting expanded clinical and corporate activities

Company press release: ID:nACS4rBw4a

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
 
$0.21
 
Q2 Net Loss
 
$11.70 mln
 
Q2 Operating Expenses
 
$11.50 mln
 

Reuters Recommended Reads
Aug 11 - Veradermics Q2 net loss widens on higher expenses
Aug 12 - Aprea Therapeutics Q2 net loss widens on higher R&D costs
Aug 12 - Turn Therapeutics Q2 net loss per share widens on higher R&D costs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)